| Literature DB >> 34440313 |
Yoshihisa Matsumoto1, Anie Day D C Asa1, Chaity Modak1, Mikio Shimada1.
Abstract
The DNA-dependent protein kinase (DNA-PK) is composed of a DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and Ku70/Ku80 heterodimer. DNA-PK is thought to act as the "sensor" for DNA double-stranded breaks (DSB), which are considered the most deleterious type of DNA damage. In particular, DNA-PKcs and Ku are shown to be essential for DSB repair through nonhomologous end joining (NHEJ). The phenotypes of animals and human individuals with defective DNA-PKcs or Ku functions indicate their essential roles in these developments, especially in neuronal and immune systems. DNA-PKcs are structurally related to Ataxia-telangiectasia mutated (ATM), which is also implicated in the cellular responses to DSBs. DNA-PKcs and ATM constitute the phosphatidylinositol 3-kinase-like kinases (PIKKs) family with several other molecules. Here, we review the accumulated knowledge on the functions of DNA-PKcs, mainly based on the phenotypes of DNA-PKcs-deficient cells in animals and human individuals, and also discuss its relationship with ATM in the maintenance of genomic stability.Entities:
Keywords: Ataxia–telangiectasia mutated (ATM); DNA damage response; DNA double-stranded break (DSB); DNA-dependent protein kinase (DNA-PK); DNA-dependent protein kinase catalytic subunit (DNA-PKcs); Ku; phosphatidylinositol 3-kinase-like kinase (PIKK); protein kinase
Mesh:
Substances:
Year: 2021 PMID: 34440313 PMCID: PMC8394720 DOI: 10.3390/genes12081143
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1The similarity of DNA-PKcs to ATM and other PIKKs. (a) The architecture of DNA-PKcs, ATM and other PIKKs. FAT: FRAP-ATM-TRRAP, PRD: PIKK-regulatory and FATC: FAT C-terminal. (b) The mechanisms of the recruitment of DNA-PKcs, ATM and ATR to DSB and ssDNA.
Figure 2Simplified diagram of DSB repair through NHEJ.
DNA-PKcs-deficient cell lines.
| Cell | Species | Type | Mutation 1 | DNA-PKcs Status | Characteristics | Ref. |
|---|---|---|---|---|---|---|
|
| Mouse | Fibroblast | HMZ | Protein very low (~1%); DNA binding undetectable; | Increased IR-sensitivity; Reduced DSB repair ability; Defective V(D)J recombination. | [ |
| V3 | Hamster | Ovary | CHTZ; | Protein undetectable; | Increased IR-sensitivity; Defective V(D)J recombination. | [ |
| M059J | Human | Glioma | LOH; | Protein undetectable; | Increased IR-sensitivity. | [ |
| Irs-20 | Hamster | Ovary | CHTZ | Protein reduced (~10% 2); | Increased IR-sensitivity; Defective V(D)J recombination. | [ |
| SX-9 | Mouse | Mammary carcinoma | CHTZ | Protein reduced (~5% 2); | Increased IR-sensitivity; Defective V(D)J recombination. | [ |
| XR-C1 | Hamster | Ovary | Unknown. | Protein undetectable; | Increased IR- and drug (bleomycin and ethyl methane sulfonate) sensitivity; Defective V(D)J recombination. | [ |
| XR-C2 | Hamster | Ovary | c.G12353A, p.G4118E. | Protein expression normal; | Increased IR- and drug (bleomycin, ethyl methane sulfonate and mitomycin C)-sensitivity; Reduced DSB repair ability; Defective V(D)J recombination. | [ |
| (Generated by gene targeting or genome editing) | ||||||
| DT40 | Chicken | B lymphocyte | p. 2888–3012. | Protein undetectable. | Normal proliferation; Increased IR-sensitivity. | [ |
| HCT116 | Human | Colon cancer | p. 3831–4127. | Protein undetectable; | Reduced proliferation; Increased IR-, drug (etoposide)-sensitivity; Telomere shortening; Increased chromosomal aberrations. | [ |
| TK6 | Human | B lymphocyte | Part of exon 32 replaced with drug resistance gene. | Protein undetectable. | Increased IR-sensitivity. | [ |
| HAP1 | Human | Fibroblast-like, near haploid | 11 bp deletion in exon 25. | Protein undetectable. | Increased drug (Etoposide)-sensitivity. | [ |
| mESC | Mouse | Embryonic stem | c.24del88; p.R9Wfs7*. | mRNA very low (<1%). | Upregulation of pluripotency genes. | [ |
| HeLa | Human | Cervical | Targeting exon 36. | Protein undetectable. | Increased IR-sensitivity. | [ |
1 HMZ: homozygote, CHTZ: compound heterozygote and LOH: loss of heterozygosity. Numbers in parentheses indicate the number of amino acids of the full-length DNA-PKcs in the respective species. 2 Estimated from the intensity of the Western blotting bands in the references.
V(D)J recombination defects in DNA-PKcs-deficient cells.
| Cell | Signal Joint | Coding Joint | Ref. | ||
|---|---|---|---|---|---|
| Frequency | Structure | Frequency | Structure | ||
| Mouse | Normal. | Fidelity slightly decreased (~80%). | Significant decrease (~3%). | Larger deletions. | [ |
| V3 | Mild decrease (~20%). | Fidelity modestly decreased (~50%). | Significant decrease (~1%). | Abnormally large P elements. | [ |
| Mouse | Substantial decrease (~10%). | Not described. | Significant decrease (~0.1%). | Not described. | [ |
| IRS-20 | Substantial decrease (~10%). | Fidelity slightly decreased (~75%). | Significant decrease (~3%). | Smaller deletions than | [ |
| SX-9 | Substantial decrease (~10%). | Fidelity profoundly decreased (~10%). | Significant decrease (~3%). | Slightly longer deletions. | [ |
| XR-C1 | Significant decrease (~2%). | Correct joins absent (0%). | Significant decrease (~2%). | Not described. | [ |
| XR-C2 | Mild decrease (~30%). | Not described. | Mild decrease (~50%). | Not described. | [ |
| xrs6 | Significant decrease (~5%). | Fidelity profoundly decreased (~15%). | Significant decrease (~1%). | None recovered. | [ |
| XR-V15B | Undetectable (<1%). | Not described. | Undetectable (<1%). | Not described. | [ |
| XR-1 | Significant decrease (~2%). | Fidelity profoundly decreased (~20%). | Significant decrease (~0.2%). | Larger deletions. | [ |
DNA-PKcs-deficient animals.
| Animal | Mutation | DNA-PKcs Status | Animal Phenotype | Cellular Phenotype 1 | Ref. |
|---|---|---|---|---|---|
| Mouse | c.T12138A, p.Y4046X. | Protein very low (~1%); | SCID; Increased thymic lymphomas. | Increased IR-sensitivity; Reduced DSB repair ability; Defective V(D)J recombination (CJ but not SJ). | [ |
| Mouse, gene knockout | Insertion of drug resistance gene in exon 6. | mRNA undetectable; | SCID. | Increased IR-sensitivity. | [ |
| Mouse, gene knockout | p. 3860–3950. | Protein undetectable; | SCID. | Defective V(D)J recombination (CJ but not SJ); Increased IR-sensitivity (fibroblast); Normal IR-sensitivity (ES). | [ |
| Mouse, gene knockout | 3′-half of exon 3 replaced with drug resistance gene. | Protein undetectable. | SCID. | Increased IR-sensitivity. | [ |
| Mouse | A transgene inserted by > 20 copies to upstream of three exons corresponding to 777–1010 nucleotides of mRNA. | mRNA undetectable; | SCID; Increased thymic lymphomas. | Not described. | [ |
| Mouse, KD | c.A11765C, | Protein expression normal; | Embryonic lethal (E14.5); Defective neuronal development. | Increased IR-sensitivity; Increased genomic instability; Defective V(D)J recombination (CJ and SJ). | [ |
| Mouse, | c.A7813/7900 | Protein expression normal; | Born at normal ratio and size, but becomes smaller 2–3 weeks of age; Death shortly after birth (75% within 4 w); Congenital bone marrow failure; Loss of hematopoietic stem cells. | Increased sensitivity to IR, UV, CPT and MMC. | [ |
| Mouse, | c.C6418T, p.R2140C/c.A11530G, p.M3844V. | Protein expression decreased (5–10%); | Immunologically normal; Normal development; Increased thymocyte apoptosis; Susceptible to cancer, including breast cancer and thymic lymphoma. | Delay in DSB repair; Increased chromosome instability. | [ |
| Horse SCID | c.9478del5, p.S3160Nfs4*. | Protein undetectable; | SCID. | Increased IR-sensitivity; Defective V(D)J recombination (CJ and SJ). | [ |
| Dog SCID | c.G10879A, p.E3627X. | Protein undetectable; | SCID. | Increased IR-sensitivity; Defective V(D)J recombination (CJ and SJ). | [ |
| Rat, gene knockout | Deletion in exon 1, causing frame-shift. | mRNA undetectable; | SCID; | Reduced proliferation; Premature senescence; IR-sensitivity; Defective NHEJ. | [ |
| Zebrafish, gene knockout | Frame-shift in exon 3. | Protein undetectable. | SCID; | Not described. | [ |
| Zebrafish, gene knockout | c.10835del8, p.D3612Vfs17. | Not described. | SCID; | Not described. | [ |
1 CJ: coding joint and SJ: signal joint.
Gene knockout mice of DNA-PKcs and other NHEJ genes.
| Mice | Viability | Growth | Neurogenesis | Immunity 1 | Ref. |
|---|---|---|---|---|---|
| DNA-PKcs−/− | Viable. | Normal body size. | Normal. | SCID (leaky); SJ: normal or modestly impaired; CJ: impaired. | [ |
| Ku80−/− | Viable. | Reduced body size. | Defective (milder than XRCC4−/− and LIG4−/−); Increased cell death. | SCID; SJ & CJ: defective. | [ |
| Ku70−/− | Viable. | Reduced body size. | Defective (milder than XRCC4−/− and LIG4−/−); Increased cell death. | SCID (leaky); SJ & CJ: defective. | [ |
| LIG4−/− | Late embryonic lethality (>E13.5) | Reduced body size in uterus. | Severely defective; Massive cell death. | SCID; SJ & CJ: defective. | [ |
| XRCC4−/− | Late embryonic lethality (>E13.5) | Reduced body size in uterus. | Severely defective; Massive cell death. | SCID; SJ & CJ: defective. | [ |
| Artemis−/− | Viable. | Normal body size. | Normal. | SCID (leaky); SJ: normal; CJ: impaired. | [ |
| XLF−/− | Viable. | Normal body size. | Normal. | Mostly normal; Slight decrease in the number of lymphocytes; Normal lymphocyte distribution; Mild defect in CSR. | [ |
| PAXX−/− | Viable. | Normal body size. | Normal. | Mostly normal; Modest decrease in the number of lymphocytes. | [ |
1 SJ: signal joint formation and CJ: coding joint formation.
Human patients deficient in DNA-PKcs.
| Patient | Gender | Ethnic Origin | Mutation 1 and DNA-PK Status | Clinical Characteristics | Cellular Characteristics | Ref. |
|---|---|---|---|---|---|---|
| P1 | F | Turkish | HMZ | SCID. | Increased IR-sensitivity; Delay in DSB repair. | [ |
| P2 | M | British | CHTZ; | SCID; Growth failure; Microcephaly; Facial dysmorphism; Seizures; Bilateral sensorineural hearing loss; Visual impairment; Died at 31 months. | Increased IR-sensitivity; Delay in DSB repair. | [ |
| P3 | M | Turkish | HMZ | SCID; Granuloma; Autoimmunity. | Not described. | [ |
| P4 | F | Turkish | HMZ | SCID; Granuloma; Autoimmunity. | Not described. | [ |
| P5 | F | Turkish | HMZ | SCID; Granuloma; Arthritis. | Not described. | [ |
| P6 | F | Turkish | HMZ | SCID; Granuloma; Diarrhea. | Not described. | [ |
1 HMZ: homozygote and CHTZ: compound heterozygote. 2 Estimated from the intensity of the Western blotting bands in the references.